j Allergan, Marlow , UK tions, respectively. An intraocular pressure increase of >25 mm Hg was recorded in 20% of patients, and 34% of patients began treatment with anti-glaucoma medication, but surgery was not needed for this condition. Conclusions: DEX implant 0.7 mg was found to be well tolerated and effective with repeat treatments in clinical practice.
(CRVO), which can be persistent and difficult to treat [1] . In July 2010, dexamethasone (DEX) intravitreal implant 0.7 mg (Ozurdex ® , Allergan Inc., Irvine, Calif., USA) was approved in the European Union for the first-line treatment of ME secondary to BRVO or CRVO, although some patients in Germany have received DEX implant 0.7 mg as part of an early access programme since October 2009. DEX implant 0.7 mg represents a novel intravitreal drug delivery system consisting of a biodegradable copolymer of lactic acid and glycolic acid, which contains micronised DEX. This corticosteroid has been shown to suppress inflammation [2] , a key event in the pathophysiology of RVO and development of ME, by inhibiting major inflammatory mediators that are associated with disease severity [3] . DEX implant 0.7 mg delivers 0.7 mg total dose of DEX to the vitreous with gradual release over time allowing for sustained drug levels to the target areas while reducing the potential for side effects typically observed from steroid administration. The DEX implant 0.7 mg has been shown to be efficacious in clinical trials in patients with inflammation of the posterior segment of the eye in non-infectious uveitis. Its efficacy in patients with ME following BRVO and CRVO has also been demonstrated in clinical trials like the Global Evaluation of Implantable Dexamethasone in Retinal Vein Occlusion with Macular Edema (GENEVA) trial and others [4] [5] [6] , but less is known about the use and injection burden of the DEX implant 0.7 mg in routine clinical practice. This retrospective study was designed to review the re-injection interval, efficacy and safety of DEX implant 0.7 mg in routine clinical practice in Germany in [2009] [2010] [2011] [2012] , and therefore enhance knowledge of this treatment option.
Methods
This was a retrospective, anonymised observational data collection study conducted at 10 centres in Germany in 2009-2012 in patients with ME in RVO who were treated according to clinical need at the discretion of each investigator. The total number of patients identified at each separate centre was as follows: Bonn, n = 22; Bremen, n = 7; Karlsruhe, n = 13; Münster, n = 15; Munich/ München, n = 17; Dresden, n = 6; Heidelberg, n = 6; Ludwigshafen, n = 4; Marburg, n = 1, and München, n = 5. Of the 96 patients originally identified by the investigators, the case report forms of 9 patients were excluded from the analysis from the Bonn centre (3/22 patients), the Münster centre (2/15 patients) and the first München centre (4/17 patients). These patients were excluded due to the following major protocol deviations: (a) the patient did not receive a DEX implant 0.7 mg at the baseline visit, or (b) the patient did not receive a minimum of 2 DEX implant 0.7 mg injections during the observation period. Data from 87 evaluable patients ( ∼ 91% of the original patients selected) aged >18 years, who were diagnosed with ME secondary to BRVO or CRVO, who received at least 2 injections of DEX implant 0.7 mg in the study eye, and had follow-up data for 3-6 months following their latest DEX implant 0.7 mg injection were therefore included in the analysis.
As this was a retrospective study of routine clinical practice, there were no specified retreatment criteria, and this was performed at the discretion of each investigator according to clinical need. This also meant that there was no significant delay between a diagnosis of recurrence of ME and the administration of the second DEX implant 0.7 mg injection. Data from patients who received DEX implant 0.7 mg as part of a clinical trial were excluded.
The primary endpoint was the mean time between the first and second DEX implant 0.7 mg injection. Secondary endpoints included best corrected visual acuity (BCVA) at 7-12 weeks after injection and central retinal thickness (CRT) measured by optical coherence tomography. Individual BCVA values were recorded in Snellen, but for the statistical analysis, the formula from Gregori et al. [7] was used to convert Snellen to approximate early treatment diabetic retinopathy study (ETDRS) values. The time point of 7-12 weeks was chosen for the secondary analysis based on the results of other clinical trials that suggested that after 7-12 weeks the chance of a relapse occurring is highest at this time point. In patients whose follow-up visits were not performed within 7-12 weeks, the follow-up visit closest to this time window was chosen for analysis.
Safety measures included adverse events monitoring, intraocular pressure (IOP), biomicroscopy and ophthalmoscopy. Data were collected and entered into a case report form, which was monitored centrally. Data were validated by a contract research organisation, MEDIDATA, and a statistical analysis plan was produced prior to database lock. Statistical analysis of the data was undertaken using statistical analysis software (SAS version 9.1) and MEDIDATA's own software, and descriptive statistics were obtained. This included preparation of data listings and summary statistics (extreme values, interquartile section, mean and median values, standard deviation) or frequency distribution tables as appropriate for each item. In this analysis, baseline was considered to be the patient's first DEX implant 0.7 mg injection.
Results

Baseline Characteristics and Demographics
Data from 87 (46 BRVO, 41 CRVO) patients were included in this retrospective study ( table 1 ) . At baseline, past and/or concomitant systemic conditions were reported for 72.4% (63/87) of the patients overall. The most frequent medical conditions were cardiovascular disorders, which were reported by 71.4% (45/63) of patients with medical conditions overall. The frequency of cardiovascular disorders was similar in the BRVO and CRVO subgroups [71.7% (33/46) and 73.1% (30/41)], respectively. Other medical conditions were reported less frequently.
Patient ocular comorbidities are shown in table 1 . A history of glaucoma at baseline was reported by 14 pa-tients (7 patients each in the BRVO and CRVO subgroups) and prior to the start of treatment with DEX implant 0.7 mg, 14.9% (13/87) of all patients suffered from glaucoma and 1 patient from ocular hypertension. Thirty-four out of the 87 patients had a pseudophakic eye. Concerning past ocular surgeries and treatments, cataract surgery was recorded in 39.0% (34/87) of patients, focal retinal laser treatment in 17.2% (15/87) of patients, panretinal photocoagulation in 14.9% (13/87) of patients, anti-glaucoma medication to treat elevated IOP in 13.8% (12/87) of patients (2 patients with glaucoma/ocular hypertension did not receive treatment for this condition), pars plana vitrectomy in 9.2% (8/87) of patients, laser peripheral iridotomy in 1 patient, with other ocular treatment recorded in 16.1% (14/87) of patients overall. The frequency of these events was similar in the BRVO and CRVO subgroups apart from laser peripheral iridotomy, which was only reported for a single patient in the BRVO subgroup.
As shown in table 1 , overall, 67% were men and the mean age was 68 years (range 47-86 years). Mean baseline visual acuity was lower, and mean CRT was greater ETDRS value is approximate and calculated based on a formula [7] , with n = 78 for RVO overall, n = 39 for BRVO and n = 43 for CRVO. The mean time from the first injection to the last follow-up visit (when the patient may or may not have been retreated) was 273.25 ± 96.06 days (range 98.0 -548.0 days) for the RVO population (n = 84), 297.43 ± 95.99 days (range 117.0 -548.0 days) for the BRVO subgroup (n = 46) and 243.97 ± 88.80 days (range 98.0 -467.0 days) for the CRVO subgroup (n = 38).
a Missing data for n = 29 (33%); b missing data for n = 19 (41%); c missing data for n = 10 (24%).
DEX Intravitreal Implant for ME for the CRVO population at baseline than for the BRVO population. Over half of the patients in this study (53%) had previously received treatment for RVO prior to receiving DEX implant 0.7 mg therapy, and the majority of these (85%) had received anti-vascular endothelial growth factor therapy. The mean time from the first injection to the last follow-up visit (when the patient may or may not have been retreated) was 273.25 ± 96.06 days (range 98.0-548.0 days) for the RVO population (n = 84), 297.43 ± 95.99 days (range 117.0-548.0 days) for the BRVO subgroup (n = 46) and 243.97 ± 88.80 days (range 98.0-467.0 days) for the CRVO subgroup (n = 38).
Efficacy Results
Data were analysed from 87 patients who received at least 2 injections of DEX implant 0.7 mg and had the required 3-6 months of follow-up data following their last DEX implant 0.7 mg injection. Of these 87 patients, 17 patients (19.5%) received a third injection of DEX implant 0.7 mg and 3 patients (3.4%) received a fourth injection. Sole treatment with DEX implant 0.7 mg was given to 39 out of 46 patients (84.8%) with BRVO and 39 out of 41 patients (95.1%) with CRVO during the course of the observation period.
Primary Efficacy Endpoint of Time to DEX Implant 0.7 mg Re-Injection
The mean time to DEX implant 0.7 mg re-injection between the first and second treatments was 141 days (5.03 months) for RVO overall, 153 days (5.46 months) for the BRVO subpopulation and 127 days (4.52 months) for the CRVO subpopulation, as shown in figure 1. Median re-injection intervals were 135 days [interquartile range (IQR) 99-169], 145 days (IQR 108-178) and 122 days (IQR 84-147) for RVO overall, BRVO and CRVO, respectively.
Secondary Efficacy Endpoints
Mean Change in BCVA from Baseline at Approximately 7-12 Weeks after the Last DEX Implant 0.7 mg Injection (ETDRS Equivalents) As shown in figure 2 , a mean approximate ETDRS letter gain of 9 ± 20.42 letters was observed at a mean time of 77 ± 37.70 days (2.75 months) following the last DEX implant 0.7 mg injection in the RVO population. In the BRVO and CRVO subpopulations, mean gains observed were 6 ± 17.68 letters after 73 ± 29.57 days (2.61 months) and 12 ± 22.67 letters after 80 ± 45.40 days (2.86 months), respectively.
Sub-Analysis Showing Mean Change in BCVA by
Baseline Duration of ME at Approximately 7-12 Weeks after the Last DEX Implant 0.7 mg Injection (ETDRS Equivalents) As shown in figure 3 , patients with ME of <90 days' duration at baseline showed greater improvements in BCVA following treatment with DEX implant 0.7 mg compared with the population as a whole (e.g. patients with ME of any duration). In the RVO group of patients with ME of <90 days at baseline (n = 27), the mean change in BCVA from baseline was 15.63 ± 22.88 letters, with a mean time between the last injection and visit of 65.52 ± 41.45 days. The corresponding changes in BCVA from baseline for the BRVO (n = 13) and CRVO (n = 14) subpopulations were 9.62 ± 20.79 letters and 21.21 ± 24.05 letters, respectively, and the mean time between the last injection and visit was 63.46 ± 29.84 days and 67.43 ± 51.05 days, respectively. Results for the BRVO and CRVO subgroups were similar although the data must be interpreted with caution as only a small number of patients were included in each group.
Patients Who Achieved a ≥ 2-or 3-Line Improvement in BCVA During the review period, 56.3% (49/87) of RVO patients achieved an improvement of ≥ 2 lines compared with baseline, in a mean time of 65 days after the first injection (n = 42; range 27-184 days) and 47 days after the second injection (n = 6; range 7-119 days). In the BRVO and CRVO subpopulations, 47.8% (22/46) of the BRVO patients and 65.8% (27/41) of the CRVO patients showed ≥ 2 lines of BCVA improvement. In the BRVO group, the mean time to a ≥ 2-line improvement was seen at 69 days after the first injection (n = 17; range 31-184 days) and at 38 days after the second injection (n = 4; range 27-55 days). In the CRVO group, the mean time to this improvement was at 62 days after the first injection (n = 25; range 27-118 days) and at 63 days after the second injection (n = 2; range 7-119 days). While it is expected that the time interval between injections would be approximately the same, the small difference seen could be explained by the small number of patients who required a second or third injection.
In the RVO patients, 50.5% (44/87) showed an improvement of ≥ 3 lines in comparison to baseline, and this was achieved 69 days after the first injection (n = 35; range 27-208 days) and 50 days after the second injection (n = 9; range 1-160 days). The sub-analyses for the BRVO and CRVO population showed that 41.3% (19/46) of all BRVO patients and 60.9% (25/41) of the CRVO patients achieved an improvement of ≥ 3 lines compared with baseline. In the BRVO group, the mean time to this improvement of ≥ 3 lines was achieved 79 days after the first injection (n = 13; range 31-208 days) and 41 days after the second injection (n = 6; range 1-74 days). For the CRVO group, the time to this improvement was 63 days after the first injection (n = 22; range 27-118 days) and 67 days after the second injection (n = 3; range 7-160 days).
Mean Change in Retinal Thickness
Reductions in CRT were seen at all time points during the study. For the 7-to 12-week post-injection time point, reductions in CRT compared with baseline were achieved after the first and second injection of as well as after the last injection of DEX implant 0.7 mg, as shown in table 2 .
Safety Findings
Adverse Events and Serious Adverse Events Adverse events were recorded for 48.3% (42/87) of patients, and table 3 shows the adverse events that were re- Mean change in BCVA from baseline. ETDRS value is approximate and calculated based on a formula by Gregori et al. [7] . Mean change in BCVA from baseline for the subgroup with ME of <90 days at baseline. ETDRS value is approximate and calculated based on a formula by Gregori et al. [7] . DEX Intravitreal Implant for ME Ophthalmologica 2015;233:18-26 DOI: 10.1159/000368840 23 ported in >1 patient. The most frequently recorded adverse event was IOP increase, which occurred in 18.4% (16/87) of all RVO patients. Other adverse events reported by more than 10% of patients included glaucoma (11.5%, 10/87) and eye laser surgery (10.3%, 9/87).
During the review period, 6.9% of patients (6/87) reported a serious adverse drug reaction; however, if cataract progression or surgery are excluded, as these events were not related to the injection procedure itself, this drops to 2.3%. 1 One operation took place after the end of the formal data collection period. When the DEX implant 0.7 mg injections were performed during a visit, pre-injection pressures have been included for the mean calculation. The mean time from the first injection to the last follow-up visit (when the patient may or may not have been retreated) was 273. 25 Out of the 6 events reported, the following were assessed by the investigator as having a casual or possible causal relationship with DEX implant 0.7 mg: 1 case of bulbar hypotension with choroidal detachment, which later resolved, 1 case of increased lens opacity and 2 cases of cataract surgery. One further cataract surgery and 1 hospitalisation due to suspected glaucoma were reported as serious adverse events, but due to the retrospective nature of this study, it was not possible for the investigator to assign a causal relationship.
Special Interest Adverse Events -IOP, Glaucoma and Cataract Surgery Table 4 shows the mean IOPs that were recorded at each time point. Anti-glaucoma medication, prescribed at the investigators' discretion, was taken by 43.7% of all patients (38/87) during the observation period with 34.5% of all patients (30/87) initiating anti-glaucoma medication while receiving treatment with DEX implant 0.7 mg. No surgery for glaucoma was reported. An IOP >25 mm Hg was seen in 19.5% (17/87) of patients. Of these patients, 17.6% (3/17) were taking anti-glaucoma medication prior to the start of treatment with DEX implant 0.7 mg, whereas 82.4% (14/17) of patients began anti-glaucoma medication during the observation period.
Lens opacity was recorded in 47.1% (41/87) of patients at the baseline visit and 9.8% (4/41) of these patients had cataract surgery due to cataract progression during the mean observation period of up to 548 days (mean 273.25 ± 96.06 days). A fifth patient also had cataract surgery during the study, but data were not available on this patient's lens opacity status at baseline.
Discussion
Data from this retrospective, observational data collection study in Germany show that with repeat usage of DEX implant 0.7 mg in clinical practice, the mean time interval between the first and second injection is 5.03 months for patients with RVO (5.46 and 4.52 months in the BRVO and CRVO subpopulation, respectively). This time period of approximately 5 months is similar to data from the published GENEVA randomised controlled clinical trial [4, 5] and comparable to data from more recent real-life retrospective studies using the DEX implant 0.7 mg for ME in RVO carried out in the UK, Italy, France and the USA [8] [9] [10] [11] [12] ( table 5 ) . In these retrospective reallife studies, as well as a prospective study from Switzerland and a European multicentre study, re-injection intervals in both treatment naïve and previously treated patients were typically between 5 and 7 months, with a trend towards a longer injection interval for subsequent injections [8] [9] [10] [11] [12] [13] [14] . Many patient-specific factors are likely to impact on the need for retreatment and therefore treatment should be individualised for each patient with the retreatment decision based on clinical judgement. Regular monitoring of the patient is therefore recommended especially as for some patients the optimum retreatment interval for the DEX implant 0.7 mg may be <5 months. This approach is aligned with that suggested by Coscas et al. [14] , who recently published a retreatment algorithm for the retreatment with DEX implant 0.7 mg for ME secondary to RVO and recommend monthly examinations from 3 to 6 months following injection.
As also shown by the data obtained, repeat DEX implant 0.7 mg treatment results in lasting improvements in visual acuity and corresponding reductions in CRT in both BRVO and CRVO patients. Visual acuity improve- ments were more marked in the CRVO population than in the BRVO population. However, mean baseline visual acuity in the BRVO population was higher than in the CRVO population (59 vs. 43 approximate ETDRS letters). As previously reported in randomised clinical trials, patients with a lower visual acuity at baseline had greater improvements following treatment presumably due to a ceiling effect [4, 15] and therefore this finding is not surprising.
Data from the subgroup analysis of patients with ME of shorter duration (<90 days) and lower BCVA (<55 letters) at baseline conducted in this study indicated that these patients had greater improvements in BCVA following treatment compared with the population as a whole. This finding is consistent with the results of the GENEVA trials, Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion (BRAVO) studies, and the Standard Care versus Corticosteroid for RVO (SCORE) study [4, 5, 16, 17] . Therefore, data obtained in this observational study of German clinical practice supports the growing evidence base that early treatment is beneficial.
Expected side effects of intraocular steroid treatment include cataract formation and IOP increases as observed in previous studies with triamcinolone and fluocinolone acetonide [18] [19] [20] [21] . Over the course of this study, a low rate of cataract was reported with only 5 cataract operations performed, 4 of which were in patients who had lens opacity recorded at baseline. The majority of patients did not experience substantial IOP rises and the mean IOP at the expected peak effect for the DEX implant 0.7 mg (e.g. 7-12 weeks after injection) was 16.1 mm Hg after the first injection. The mean IOP after the second DEX implant 0.7 mg injection was 16.3 mm Hg, thereby indicating that IOP rises were similar for repeat treatment. While 34.5% of patients began anti-glaucoma medications at the investigators' discretion during the observation period, no surgery for this condition was reported. As IOP increases are known to occur with intravitreal steroids, regular monitoring and appropriate pharmacotherapy is recommended to control IOP [19, 20, 22] . As alternative treatments to intravitreal steroid implant in patients with RVO may be associated with an increased injection frequency or side effects that are less easily managed, the advantages of treatment with the DEX implant 0.7 mg may outweigh the disadvantages of steroid-related side effects such as cataract and moderate IOP increase [23, 24] .
Limitations of this study include the small number of centres and hence, patients who had data analysed (10 centres; n = 87), and its retrospective and observational nature. It is likely, however, that data obtained were reflective of clinical practice in Germany between 2009 and 2012. Larger prospective observational studies are currently underway to more fully elucidate the usage patterns of the DEX implant 0.7 mg in clinical practice, and they will allow comparisons with the results of the study reported herein.
In conclusion, the findings of this retrospective study on the efficacy and safety of DEX implant 0.7 mg in routine clinical practice in Germany in 2009-2012 are in line with those reported in similar length or long-term studies in other European and US clinical practices [8] [9] [10] [11] [12] [13] [14] 25] . A summary of the main findings from this study in comparison with other real-life studies is provided in table 5 . As confirmed in this retrospective study, treatment with DEX implant 0.7 mg had a positive effect on the final visual function and had a favourable long-term safety profile in patients with RVO. In particular, while IOP changes were seen in some patients, these could be easily controlled with medications, did not generally prevent retreatment, and surgery was not performed for IOP increase and/or glaucoma. This study demonstrated that the main benefit of treatment with the DEX implant 0.7 mg over other treatment modalities is its acceptable risk-benefit ratio and the long interval between injections. There are also likely to be cost savings from the use of the DEX implant 0.7 mg as well as an improvement in patient compliance, but further research is needed to establish this. In addition, data are awaited from the COMO study, which will allow the comparison of the relative safety and efficacy of DEX implant 0.7 mg and ranibizumab 0.5 mg, an anti-vascular endothelial growth factor medication. These are two different pharmacologic approaches that have very different mechanisms of action, and the findings of the COMO study should improve our understanding of the relative role of managing multiple inflammatory mediators in RVO. Data will also be available on the potential benefits of the different treatment schedules and the burden of the number of injections on patients and health care systems. Coupled with the findings of this retrospective, real-life study, data obtained should help determine future management choices in patients with RVO.
